X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Neoadjuvant Combo Reduces Volume of High-Risk Prostate Tumors

Neoadjuvant therapy that combines abiraterone acetate plus prednisone (AAP) and leuprolide prior to radical prostatectomy significantly reduces tumor size in men with high-risk localized prostate cancer (PCa) and may decrease the risk of biochemical recurrence compared with leuprolide alone, according to a new study.

Click here to read the full article.

source: John Schieszer - Renal and Urology News